Edgewise Therapeutics registers Phase 2 EQUINOX-HFpEF study of EDG-15400
Edgewise Therapeutics has begun recruiting for a Phase 2 trial testing EDG-15400 in patients with heart failure with preserved ejection fraction.
This week's update covers a single new trial registration from Edgewise Therapeutics.
- Edgewise Therapeutics is recruiting for "EQUINOX-HFpEF" (NCT07795814), a Phase 2 randomized, double-blind, placebo-controlled study evaluating EDG-15400 in adults with symptomatic heart failure with preserved ejection fraction.1 The trial plans to enroll 90 participants across arms testing EDG-15400 at 25 mg and 50 mg doses against placebo.1 The study's primary outcome is the incidence of treatment emergent adverse events and serious adverse events observed in patients with HFpEF.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.